Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question

Executive Summary

Pfizer Inc. on Sept. 8 released some data from three previously undisclosed pivotal trials for tofacitinib, its high-profile, first-in-class JAK3 inhibitor for rheumatoid arthritis, which it says shows that the drug is equal in efficacy to Abbott Laboratory Inc.’s bestselling TNF inhibitor Humira.
Advertisement

Related Content

Will Pharmacovigilance Be Enough To Address Questions About Pfizer’s Tofacitinib?
Tackling Mechanisms Of Disease Resistance At Janssen
Pfizer Tofacitinib’s Fate May Rest On Radiographic Data
Pfizer Downplays Risk Of Tofacitinib Panel Review As It Pushes Focus On Innovation
Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug
Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug
On Building A Better R&D Machine, Part 1: Pfizer’s R&D Chief Mikael Dolsten Talks Organizational Structure And Innovation
Pfizer Rare Disease Plans Back On Track With Resubmission of Tafamidis
Death Scare For Pfizer's Pipeline Star Tofacitinib May Be Just A Storm In a Teacup
Death Scare For Pfizer's Pipeline Star Tofacitinib May Be Just A Storm In a Teacup

Topics

Advertisement
UsernamePublicRestriction

Register

PS053770

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel